Traws Pharma, Inc. (TRAW) fundamentals score
Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 4.5 out of 10, Weak long-term fundamentals
- Growth: 5.0/10
- Profitability: 4.1/10
- Financial health: 4.9/10
- Earnings quality: 1.0/10
- Valuation: 7.0/10
Scores are calculated from Traws Pharma, Inc.’s SEC filings, using the 12 months through 2025-12. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10